How Accurate Is — a PET-CT Scan?

There is no single accuracy figure that applies to all PET-CT scans, because accuracy varies significantly by cancer type, stage, the part of the body being assessed, and the specific clinical question being asked. ESMO and NCCN guidance documents cite accuracy ranges for specific indications — lymphoma staging, lung cancer, colorectal recurrence — but those figures do not translate into a general number that applies to every scan. The more useful question to ask your oncologist is what the scan is expected to detect or rule out in your specific situation, rather than a population-level percentage.

Yes, and this is a known limitation rather than a failure of the scanner or the team. Very small deposits, cancers with low metabolic activity, and lesions in difficult locations such as the brain or mucosal bowel wall are the circumstances where a miss is most likely. This is why a clear result is described as reducing the probability of detectable active disease, not as confirming that no disease is present. Your oncologist takes this into account when deciding whether any further investigation is warranted after a clear scan.

The most common causes are active infection, tuberculosis and other granulomatous diseases, sarcoidosis, recent surgery or biopsy, and post-radiotherapy inflammation. All of these cause tissue to consume more glucose than usual, which produces increased tracer uptake that can resemble a cancer deposit on the image. When a suspicious area is found, your team will consider whether any of these explanations fit before recommending a biopsy. In some cases a follow-up scan a few weeks later helps distinguish between inflammation, which tends to settle, and cancer, which does not.

For most oncology indications, combining the metabolic information from PET with the anatomical detail from CT gives more information than CT alone — particularly for staging, assessing treatment response, and detecting recurrence. NCCN staging guidance recommends PET-CT over CT alone for several cancer types, including lymphoma and lung cancer. However, for some specific questions — fine anatomical detail in the liver, or assessing the bowel wall — CT or MRI with contrast may give more useful information than PET-CT. The right tool depends on what question is being asked, and your oncologist selects the scan based on that.

SUV stands for Standardised Uptake Value and measures how intensely a particular spot absorbed the tracer. A higher number generally suggests more metabolically active tissue, but the same value can be produced by active inflammation as by a cancer deposit. SUV also changes with blood glucose level, body composition, the time between injection and scanning, and technical processing factors. The figures in your report are interpreted by a nuclear medicine specialist or radiologist in the context of your full clinical history, not as a standalone number. Ask your oncologist what the specific values mean for you.

PET-CT scans coordinated through CION's partner imaging centres are reported by nuclear medicine physicians or radiologists with specialised training in oncology imaging. The report is then reviewed by your treating oncologist as part of your overall clinical assessment — the scan result is never used in isolation to make a treatment decision. Asking for a second opinion on a scan or its interpretation is entirely reasonable, particularly if a result is unexpected, borderline, or will have a significant effect on your treatment plan. Your oncologist can arrange a formal second read, or you can seek an independent opinion at another centre.